Intellia Thera CS (NTLA)

$8.09 -0.22 (-2.65%)
Market Cap 819.86M
Revenue (ttm) 57.88M
Net Income (ttm) -519.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -896.72%
Debt to Equity Ratio 0.00
Volume 2,562,488
Avg Vol 3,624,968
Day's Range N/A - N/A
Shares Out 103.52M
Stochastic %K 99%
Beta 2.23
Analysts Strong Sell
Price Target $42.61

Latest News on NTLA

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Apr 23, 2025, 9:50 AM EDT - 8 hours ago

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

Apr 14, 2025, 10:58 AM EDT - 9 days ago

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

Apr 10, 2025, 10:40 AM EDT - 13 days ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

Apr 9, 2025, 10:49 AM EDT - 14 days ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA

Apr 3, 2025, 1:03 PM EDT - 20 days ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit – NTLA

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Apr 3, 2025, 7:30 AM EDT - 20 days ago

Intellia Therapeutics Announces First Patient Dosed in the MAGNITUDE-2 Phase 3 Study of Nexiguran Ziclumeran (nex-z), a One-Time Gene Editing-Based Treatment for Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication

Mar 28, 2025, 6:24 AM EDT - 26 days ago

Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Mar 26, 2025, 7:30 AM EDT - 4 weeks ago

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Intellia Therapeutics, Inc. (NTLA) Barclays 27th Annual Global Healthcare Conference (Transcript)

Mar 11, 2025, 5:43 PM EDT - 6 weeks ago

Intellia Therapeutics, Inc. (NTLA) Barclays 27th Annual Global Healthcare Conference (Transcript)

Intellia Therapeutics, Inc. (NTLA) Leerink 2025 Global Biopharma Conference (Transcript)

Mar 10, 2025, 6:03 PM EDT - 6 weeks ago

Intellia Therapeutics, Inc. (NTLA) Leerink 2025 Global Biopharma Conference (Transcript)

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit - NTLA

Mar 6, 2025, 5:45 AM EST - 6 weeks ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 14, 2025 in Intellia Therapeutics, Inc. Lawsuit - NTLA

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Mar 4, 2025, 4:01 PM EST - 7 weeks ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Intellia Trades Lower After Q4 Results As Clinical Progress Fails To Impress

Mar 2, 2025, 9:30 AM EST - 7 weeks ago

Intellia Trades Lower After Q4 Results As Clinical Progress Fails To Impress

Intellia Therapeutics, Inc. (NTLA) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 12:30 PM EST - 7 weeks ago

Intellia Therapeutics, Inc. (NTLA) Q4 2024 Earnings Call Transcript

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

Feb 27, 2025, 7:30 AM EST - 7 weeks ago

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Company Progress

Robbins LLP Reminds Intellia Therapeutics, Inc. (NTLA) Investors with Large Losses to Contact the Firm to Learn How They Can Recover for Their Losses

Feb 26, 2025, 8:56 PM EST - 7 weeks ago

Robbins LLP Reminds Intellia Therapeutics, Inc. (NTLA) Investors with Large Losses to Contact the Firm to Learn How They Can Recover for Their Losses

Shareholders of Intellia Therapeutics, Inc. Should Contact The Gross Law Firm Before April 14, 2025 to Discuss Your Rights – NTLA

Feb 26, 2025, 1:31 PM EST - 2 months ago

Shareholders of Intellia Therapeutics, Inc. Should Contact The Gross Law Firm Before April 14, 2025 to Discuss Your Rights – NTLA

NTLA Investors are Suing Intellia Therapeutics, Inc.; Contact Robbins LLP for More Information

Feb 20, 2025, 5:39 PM EST - 2 months ago

NTLA Investors are Suing Intellia Therapeutics, Inc.; Contact Robbins LLP for More Information

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates

Feb 20, 2025, 7:30 AM EST - 2 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates

Rosen Law Firm Urges Intellia Therapeutics, Inc. (NASDAQ: NTLA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

Feb 13, 2025, 12:29 PM EST - 2 months ago

Rosen Law Firm Urges Intellia Therapeutics, Inc. (NASDAQ: NTLA) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights